About Careers MedBlog Contact us

New Drug to Treat Lymphoma Shows Promise When Tested on Dogs

by Savitha C Muppala on September 8, 2010 at 7:27 PM
Font : A-A+

 New Drug to Treat Lymphoma Shows Promise When Tested on Dogs

Researchers have zeroed in on a novel target for the treatment of lymphoma and are now evaluating the efficacy of the drug by testing it on pet dogs afflicted with the disease.

The results of the study, conducted by researchers at the University of Illinois, appear this month in the journal Cancer Research.The new compound targets a cellular enzyme, procaspase-3, that when activated spurs a cascade of reactions that kill the cell, said chemistry professor Paul Hergenrother, who co-led the study with Tim Fan, a professor of veterinary clinical medicine.


Procaspase-3 offers an attractive target for cancer therapy, in part because cancers often interfere with normal cell death, and in part because many tumors - including those found in breast cancer, colon cancer, lung cancer, lymphoma, melanoma and liver cancer - contain high levels of procaspase-3.

"In my lab, we try to think of novel targets and novel approaches to cancer and other diseases," Hergenrother said. "We think about the pathways that lead to those diseases, and we try to intervene at spots where others have not."The new compound is a modified version of a drug the researchers previously tested in mice and one dog.

Source: Eurekalert

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New Drug to Treat Lymphoma Shows Promise When Tested on Dogs Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests